Drug Trial Radar · NCT06040086
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,454
Actual
Start
Sep 22, 2023
Primary completion
Mar 6, 2026
Study completion May 22, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with symptomatic COPD with a history of ≥ 2 moderate or ≥ 1 severe exacerbations of COPD in the 12 months prior to enrolment. Participants should be receiving optimised treatment with inhaled maintenance therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) throughout at least the last 3 months prior to enrolment.
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
PlaceboDrug
Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study.
TozorakimabDrug
Administered subcutaneously tozorakimab and placebo throughout the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.Time frame: Over 52 weeks
Locations
368 sites in 29 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Decatur, Alabama
Research Site
Sheffield, Alabama
Research Site
Phoenix, Arizona
Research Site
Tucson, Arizona
Research Site
Yuma, Arizona
Research Site
Los Angeles, California
Research Site
Newport Beach, California
Research Site
San Francisco, California
Research Site
Westminster, California
Research Site
Aurora, Colorado
Research Site
Boulder, Colorado
Research Site
Washington D.C., District of Columbia
Research Site
Boynton Beach, Florida
Research Site
Cape Coral, Florida
Research Site
Lakeland, Florida
Research Site
Lakeland, Florida
Research Site
Naples, Florida
Research Site
Ocala, Florida
Research Site
Ormond Beach, Florida
Research Site
Atlanta, Georgia
Research Site
Lithonia, Georgia
Research Site
Champaign, Illinois
Research Site
Chicago, Illinois
Research Site
Chicago, Illinois
Research Site
Andover, Kansas
Research Site
Bowling Green, Kentucky
Research Site
Lexington, Kentucky
Research Site
Towson, Maryland
Research Site
Detroit, Michigan
Research Site
Minneapolis, Minnesota
Research Site
Chesterfield, Missouri
Research Site
Chesterfield, Missouri
Research Site
Hannibal, Missouri
Research Site
Papillion, Nebraska
Research Site
Las Vegas, Nevada
Research Site
Toms River, New Jersey
Research Site
The Bronx, New York
Research Site
Charlotte, North Carolina
Research Site
Greenville, North Carolina
Showing 40 of 368 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.